In Type IIb von Willebrand Disease, what phenomenon occurs due to the "gain of function" defect?

In Type IIb von Willebrand Disease, what phenomenon occurs due to the "gain of function" defect?

• A. Severe bleeding episodes
• B. Increased binding of platelets to vWF
• C. Decreased multimer formation
• D. Normal platelet clearance

Answer: (B)

In Type IIb von Willebrand Disease, a "gain of function" defect in von Willebrand factor (vWF) leads to an abnormal increase in the binding of platelets to vWF. This condition results from mutations that enhance the interaction between vWF and platelets, particularly under low shear stress conditions. The increased binding can lead to excessive platelet aggregation, which paradoxically causes a consumption of platelets and contributes to bleeding problems. In this context, while one would expect that increased platelet binding should enhance hemostasis, the dysregulation resulting from this gain of function actually leads to the formation of microthrombi and subsequent thrombocytopenia, which exacerbates bleeding tendencies. The other options do not accurately describe the primary pathological mechanism associated with Type IIb. For instance, severe bleeding episodes can occur but are not the defining feature of this subtype. Decreased multimer formation is more characteristic of Type I von Willebrand Disease, where there is reduced production of vWF. Normal platelet clearance is not directly relevant to the mechanisms at play in Type IIb, where platelet interactions with vWF are disrupted due to their increased binding capacity, leading to clinical challenges.

In Type IIb von Willebrand Disease, a "gain of function" defect in von Willebrand factor (vWF) leads to an abnormal increase in the binding of platelets to vWF. This condition results from mutations that enhance the interaction between vWF and platelets, particularly under low shear stress conditions.

The increased binding can lead to excessive platelet aggregation, which paradoxically causes a consumption of platelets and contributes to bleeding problems. In this context, while one would expect that increased platelet binding should enhance hemostasis, the dysregulation resulting from this gain of function actually leads to the formation of microthrombi and subsequent thrombocytopenia, which exacerbates bleeding tendencies.

The other options do not accurately describe the primary pathological mechanism associated with Type IIb. For instance, severe bleeding episodes can occur but are not the defining feature of this subtype. Decreased multimer formation is more characteristic of Type I von Willebrand Disease, where there is reduced production of vWF. Normal platelet clearance is not directly relevant to the mechanisms at play in Type IIb, where platelet interactions with vWF are disrupted due to their increased binding capacity, leading to clinical challenges.